Clinical trials
Colorectal Cancer (MSI-H) clinical trials
Below are recruiting colorectal cancer (msi-h) clinical trials, each written for real people, not researchers. We’re tracking 104 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06959589Enrolling by invitationPhase 2
Combination therapy for KRAS G12C mutated colorectal cancer
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
Hangzhou, ZhejiangAges 18–75 - NCT06959550RecruitingPhase 2
Ivonescimab for previously treated metastatic colorectal cancer
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
Houston, TexasAges 18 years+ - NCT05771181RecruitingPhase 2
Test vitamin E plus two cancer drugs for metastatic colon cancer
This trial tests whether adding vitamin E to two cancer medicines (fruityquintinib and tislelizumab) can work better in people with metastatic colorectal cancer that is mismatch-repair stable (MSS). It may help if your cancer has grown despite standard treatment, and you can meet the study’s safety and blood/organ requirements.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06936527Enrolling by invitationPhase 1/Phase 2
XS-03 plus chemotherapy and bevacizumab for metastatic colorectal cancer with RAS mutation
This trial tests an experimental drug called XS-03 combined with standard chemotherapy (FOLFOX or FOLFIRI) plus a targeted therapy (bevacizumab) for people with metastatic colorectal cancer that has a RAS mutation. The goal is to see if adding XS-03 helps shrink tumors or slows cancer growth better than current treatments.
BeijingAges 18–75 - NCT06903858RecruitingPhase 2
Toripalimab plus celecoxib for dMMR/MSI-H colorectal cancer
This trial tests whether combining toripalimab (an immunotherapy) with celecoxib (an anti-inflammatory drug) can shrink locally advanced colorectal tumors that have specific genetic features (dMMR or MSI-H). It aims to help people who haven't had any prior treatment for their colorectal cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06878131Recruiting
Precision-MRD: Targeted therapy study for colorectal cancer with MRD
This study looks at how well targeted therapies work for people with colorectal cancer who have minimal residual disease (MRD, tiny amounts of cancer left after treatment) detected by a blood test. It is for people who have a specific genetic change (biomarker) in their tumor and have not been treated with the targeted therapy for that biomarker before.
Houston, TexasAges 18 years+ - NCT06714357RecruitingPhase 2
Valproic Acid to Boost Anti-EGFR in Colorectal Cancer
This trial tests whether adding valproic acid to standard anti-EGFR plus irinotecan can stop or reverse resistance in metastatic colorectal cancer. It is for patients who previously responded well to an anti-EGFR drug and then progressed.
Caserta, CEAges 18 years+ - NCT06696768RecruitingPhase 1
New drug plus standard chemotherapy for advanced colorectal cancer
This trial combines a new experimental drug (emavusertib) with standard chemotherapy (FOLFOX plus bevacizumab) for people with stage IV colorectal cancer who have not yet received chemotherapy. The goal is to see if the combination is safe and effective, potentially offering a new first-line treatment option.
Gainesville, FloridaAges 18 years+ - NCT06589830RecruitingPhase 2
TL938 with Trastuzumab for HER2+ Colorectal Cancer
This trial is testing a new combination of drugs (TL938 and trastuzumab) for people with a specific type of advanced colorectal cancer that is HER2-positive and RAS wild-type. It may offer a new option if you have already tried standard chemotherapy and a blood vessel-blocking drug.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06562192RecruitingPhase 1
Testing a radioactive drug for advanced pancreatic, lung, breast, and colorectal cancers
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
Birmingham, AlabamaAges 18–100 - NCT06562543RecruitingPhase 4
Fruquintinib for advanced colorectal cancer in minority populations
This trial tests a medication called fruquintinib (an oral pill) for people with advanced colorectal cancer that has not responded to prior treatments. It is specifically looking for participants who identify as Black or African American and/or Hispanic or Latino to help understand how the drug works in these groups.
Birmingham, AlabamaAges 18 years+ - NCT06353854Recruiting
Study of biomarkers in MSI-high colorectal cancer patients on immunotherapy
This trial is studying people with a specific type of advanced colorectal cancer (MSI-high/dMMR) who are starting immunotherapy with pembrolizumab. The goal is to find out which markers in the tumor might predict whether the treatment works well.
BayonneAges 18 years+ - NCT06205836RecruitingPhase 2
Cemiplimab with or without Fianlimab for MSI-H Colorectal Cancer in Older Patients
This trial tests a new immunotherapy combination for older patients with a specific type of colorectal cancer that has not been treated before. The goal is to see if these drugs can help the immune system fight the cancer without needing surgery or standard chemotherapy.
Baltimore, MarylandAges 18 years+ - NCT06002789RecruitingPhase 2
PD-1 immunotherapy with or without chemo before surgery for colorectal cancer
This trial tests a medicine called PD-1 (a type of immunotherapy that helps your immune system fight cancer), sometimes with chemotherapy, before surgery for a certain type of colorectal cancer. It is for people whose tumors have a specific DNA repair problem (dMMR or MSI-H) and whose cancer has not spread to distant organs.
Guangzhou, GuangdongAges 18–80 - NCT03926338RecruitingPhase 2
Before-surgery immunotherapy for MSI-H or dMMR colon cancer
This trial studies a treatment given before surgery using toripalimab, with or without celecoxib, for colon or rectal cancer that has MSI-H or dMMR tumor features. It aims to shrink or control the cancer before the operation and compare whether adding celecoxib helps.
Guangzhou, GuangdongAges 18–75 - NCT05919264RecruitingPhase 1/Phase 2
FOG-001 for advanced solid tumors with certain gene changes
This trial tests a new drug, FOG-001, alone or with other treatments, for people with advanced solid tumors that have specific changes in the WNT pathway genes. It aims to see if the drug can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT05462236RecruitingPhase 2
Study drug AUM001 with immunotherapy or chemotherapy for metastatic colon cancer
This Phase 2 trial tests AUM001 (a targeted drug) combined with either pembrolizumab (an immunotherapy) or irinotecan (a chemotherapy) in people with metastatic colorectal cancer. It aims to shrink tumors and improve outcomes when standard treatments have already been tried.
Camperdown, New South WalesAges 18 years+ - NCT06243393RecruitingPhase 2/Phase 3
Sacituzumab govitecan for advanced colorectal cancer
This study tests a drug called sacituzumab govitecan for people with metastatic colorectal cancer who have already tried several standard treatments. It may be an option if your cancer is not MSI-H or dMMR and you haven't had irinotecan recently.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT07790510RecruitingPhase 1/Phase 2
Study of HSK42360 with cetuximab for BRAF-mutated colorectal cancer
This trial tests an experimental drug (HSK42360-Na) combined with standard treatments (cetuximab with or without chemotherapy) for people with advanced colorectal cancer that has a specific BRAF mutation. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
BeijingAges 18 years+ - NCT06425133RecruitingPhase 2
Regorafenib plus low-dose chemo for advanced colorectal cancer
This trial tests a combination of regorafenib (a targeted pill that cuts off blood supply to tumors) with a low-dose, continuous chemotherapy regimen for people whose colorectal cancer has spread and is no longer responding to standard treatments. The goal is to see if this mix can slow or stop the cancer's growth.
AuxerreAges 18 years+ - NCT07389265RecruitingPhase 3
Continuing cetuximab after first treatment stops working for metastatic colorectal cancer
This trial tests if continuing the targeted therapy cetuximab after initial treatment stops working can help people with advanced colorectal cancer. Participants have a specific gene profile (RAS and BRAF normal) and their cancer responds well at first.
AnconaAges 18 years+ - NCT07333053Recruiting
Chemotherapy through a catheter for advanced colorectal cancer
This trial tests giving chemotherapy directly into the artery that feeds the tumor, which may help control advanced colorectal cancer that cannot be removed with surgery. It is for people who have not yet had other treatments and whose main tumor is in the colon or rectum.
Xicheng, Beijing MunicipalityAges 18 years+ - NCT07309289RecruitingPhase 3
Comparing two drug combos for first-line metastatic colorectal cancer
This trial tests whether a combination of chemotherapy drugs (NALIRIFOX) plus targeted therapy works better than another standard combination (FOLFOX) plus targeted therapy for people with metastatic colorectal cancer who haven't had treatment yet. It aims to find a more effective first treatment option.
ShanghaiAges 18 years+
Hear when a new Colorectal Cancer (MSI-H) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer (msi-h)?
- Yes. Clin2 currently lists 104 recruiting colorectal cancer (msi-h) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer (msi-h) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer (msi-h) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.